Antihistamines in Topical Preparations

Total Page:16

File Type:pdf, Size:1020Kb

Antihistamines in Topical Preparations AMERICAN ACADEMY OF PEDIATRICS 299 mor appearance in young women. New Eng. 3. Herbst, A. L., Ulfelder, H., and Poskanzer, D. C.: J. Med., 284:878, 1971. Registry of clear-cell carcinoma of genital 2. Greenwald, P., Barlow, J. J., Nasca, P. C., and tract in young women. New Eng. J. Med., Burnett, W. S. : Vaginal cancer after maternal 285:407, 1971. treatment with synthetic estrogens. New Eng. 4. Folkman, J. : Transplacental cardinogenesis by J. Med., 285:390, 1971. stilbestrol. New Eng. J. Med., 285:404, 1971. ANTIHISTAMINES IN TOPICAL PREPARATIONS NTIHISTAMINES were introduced in topically. The ethylenediamine derivatives France by Halpern in 1942 and in the include the following: antazoline phosphate United States at the end of World War II; ( Antistine ), promethazine hydrochloride they had been investigated extensively dur- ( Phenergan#{176} ), and tripelennamine ( Pyri- ing the war for therapy of motion sickness. benzamine ) . They are particularly active in By the late 1940s, a mass of information on inducing contact dermatitis and were re- the structure activity relationship had accu- sponsible for the cases first reported.’#{176} mulated and most major drug manufactur- Ethylenediamine, because of its dibasic ens had introduced antihistamines into the structure, is widely used in various organic market for oral, parenteral, and topical ad- syntheses for the preparation of dyes, inhib- ministration. Topical use was efficacious in itors, rubber accelerators, fungicides, syn- acute dermatitis because the local anes- thetic waxes, resins, insecticides, and as- thetic activity of the drugs diminished pru- phalt-wetting agents. It is valuable for ritus. neutralizing the acidity of oils or controlling The first reports of sensitization to the alkalinity. As ethylenediaminetetracetic acid topical antihistamines, which began to ap- ( EDTA ), it is a ubiquitously used preser- pear in 1947, incriminated tnipelennamine vative in topical and systemic medications (Pyribenzamine), diphenhydramine ( Ben- of all types. The induction of contact sensi- adryl), antazoline (Antistine), and pheni- tivity to drugs of this class will result in a ramine (Trimeton ) ,14 In the ensuing 25 dermatitis on topical or oral readministra- years, though thousands of instances of an- tion of agents of this class of antihistamines. tihistamine contact dermatitis have oc- The sensitized patient may also react to curred, many topical antihistamines remain the oral or parenteral administration of ami- on the market. The Committee is concerned nophylline, which contains theophylline about the use of topical antihistamines conjugated with ethylenediamine, as well which are sold over the counter for use in as to contact with any of the many sub- such conditions as chickenpox and poison stances containing ethylenediamines. ivy. Table I lists most of the preparations The phenothiazines include drugs em- currently available for topical use. ployed either as antihistamines or as pay- chotrophic agents. Representative members CLASSES OF ANTIHISTAMINES of this group of compounds are given in The antihistainines are classified accord- Table II. Promethazine hydrochloride ing to their chemical structure into five pri- ( Phenergan ) is available as a topical prep- mary groups as shown in Table II. Each drug carries its own index of sensitization 0 Phenergan is both an ethlenediamine and a and other adverse effects when employed phenothiazine derivative. The statements presented herein do not preclude alternatives which may be more appropriate, taking into account local situations and all other relevant facts. Executive Board, AAP Downloaded from www.aappublications.org/news by guest on September 23, 2021 300 ANTIHISTAMINES IN TOPICAL PREPARATIONS aration. Phenothiazines are the worst topi- TABLE I cal offenders in the antihistamine group. ToPIcAL ANTIHISTAMINES Not only are they potent allergic contact sensitizers, but they may also evoke a pho- Brand Name Generic Antihistamine Manufocture toallergic contact dermatitis. Photoderma- Antiatine Solution Antazoline Ciba titis, due to allergic contactants, is often Antopic Cream Pyranisamine (maleate) Smith-Doraey Benadryl Cream Diphenhydramine Parke. Davis characterized by persistence long after re- Bristamine Lotion Phenyltoloxamine Bristol moval of the offending substance. Further- Caladryl Lotion and Cream Diphenhydramine Parke. Davis more, since light of 360 nm wavelength and Dermaval Cream Pyrilamine (maleate) Vale above is responsible, sunscreens and win- Histacairna Cream Methapyrilene Rexall Histadyl Ointment Thenylpyramine Lilly dow glass offer no protection. This type of Neohetramine Ointment Thonzylamine Nepra dermatitis can be debilitating for many Perazil Cream Chlorcyclizine Burroughs, Weilcome years and may be activated by both incan- Phenergan Cream Promethaxine Wyeth descent and fluorescent light. Once topical Prantal Cream Diphemanil Schering Pyribenzamine Cream sensitization to phenothiazines has oc- . and Ointment Tripelennamine Ciba curred, systemic administration of any Thenylene Cream Thenylpyramine Abbott Thephorin Lotion and member of this class may elicit a severe Ointment Phenidamine Roche dermatitis.7 Trimeton Ointment Prophenpyridamine Schering Ziradryl Lotion and The ethanolamine compounds include Cream Diphenhydramine Parke. Davis diphenhydramine ( Benadryl) and doxyla- mine succinate ( Decapryn). While this group of substances has a lower sensitizing ical antihistamines not be used because of potentialo than the other two, the extensive their sensitizing potential.9 use of topical diphenhydramine in the form The Committee on Drugs, on the basis of of Caladryl Lotion on Ointment has re- the foregoing evidence, urges pediatricians: sulted in frequent sensitization of children. 1. To discontinue the use of topical an- Because the resulting dermatitis usually clears promptly on removal of the drug, TABLE II cases are rarely reported. CLASSES OF ArIHIsTAMINm Alkylamines and piperazine compounds capable of inducing a contact dermatitis in- Generic Antihistamine Brand Name dude pheniramine Trimetine), phenin- ( Ethylenediamines damine (Theophorin ), and pyrilamine Tripelennamine citrate Pynbenzamine Antaxoline phosphate Antistine ( Neo-Antergan). Methapyrilene hydrochloride Histadyl COMMENT Phenothiazine, Methadilaxine Tacaryl Recently, the National Academy of Sci- Promethazine hydrochloride Phenergan Tripelennamine tartrate Temaril ences-National Research Council Drug Effi- cacy Study group evaluated a group of over Elhanolamines Diphenhydramine hydrochloride Benadryl the counter topical antihistamines. Based Carbinoxamine maleate Clistin on their report, the Food and Drug Admin- Doxylamine succinate Decapryn Succinate istration concluded that these drugs are in- .4llcylamines effective for prophylaxis against dermatitis Brompheniramine maleate Dimetane Chlorpheniramine maleate Chlor-Trimetal. Ilistaspan, caused by poison ivy and other plants of Teldnn the rhus genus. It further classified these Dexbrompheniramine maleate Disomer Dexchlorpheniramine maleate Polaramine drugs as “possibly effective” for other la- Dimethindene maleate Forhistal Maleate beled indications for dermatologic use, Tripolidine hydrochloride Actidil placing the onus on the manufacturer to Piperazines prove their efficacy.8 The American Medical Cyclizine hydrochloride Marezitie Medicine hydrochloride Bonine Association has also recommended that top- Downloaded from www.aappublications.org/news by guest on September 23, 2021 AMERICAN ACADEMY OF PEDIATRICS 301 tihistamine preparations because their tox- apy with tripelennamine hydrochloride icity exceeds their limited benefit. (“Pyribenzamine Hydrochloride”). JAMA, 134:782, 1947. 2. To discourage parents from purchas- 3. Harris, M. C., and Shure, N.: Eczematoid der- ing over the counter topical antihistamines, matitis following ingestion of “Pyribenzamine especially Benadryl, Caladryl, Ziradryl, and Hydrochloride” N.N.R. tablets. J. Allerg., 18: Pyribenzamine for use in treating chicken- 408, 1947. 4. Peck, S. M.: The role of the antihistaminic pox, poison ivy, poison oak, and other types drugs in producing cross-sensitization derma- of dermatitis. titis. New York J. Med., 50 (supplement): 3. To keep in mind the frequency of con- 2690, 1950. tact dermatitis resulting from such agents 5. Hjorth, N., and Fregert, S.: Contact dermatitis. in the evaluation of a dermatitis of un- in Rook, A., Wilkinson, D. S., and Ebling, J. C., eds.: Textbook of Dermatology. Oxford: known etiology. Blackwell Scientific Publications. 1968, pp. The Committee further urges that a 238-322. warning about the sensitizing potential of 8. Fisher, A. A. : Systemic eczematous “contact- these agents be placed on the label of these type” dermatitis medicametosa. In Fisher, preparations. A. A., ed.: Contact Dermatitis. Philadelphia: Lea & Febiger, p. 233, 1967. COMMITrEE ON DRUGS 7. Epstein, S., and Rowe, R. J.: Photoallergy and SUMNER YArn, M.D., Chairman J. photocross-sensitivity to phenergan. J. Invest. Ciirns W. BIERMAN, M.D. Derm., 29:319, 1957. Howiw M. CN, M.D. 8. Food and Drug Administration: Certain OTC ARNOLD P. GoLD, M.D. topical antihistamines, drugs for human use; drug efficacy study implementation. Federal Fiiuc M. KENNY, M.D. Register, 36:18021, 1971. Hms D. RILEY, JR., M.D. 9. Antihistamines. in AMA Drug Evaluations, ed. IRwmr ScHAFER, M.D. 1. Chicago: American Medical Association, LEO STERN, M.D. 1971, pp. 367-368. REFERENCES Acknowledgment 1. Sulzberger, M., Baer, R. L., and Levin, H. B.:
Recommended publications
  • PROZAC Product Monograph Page 1 of 49 Table of Contents
    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Opioid and Other Substance Use Disorders
    OPIOID AND OTHER SUBSTANCE USE DISODERS Dr Amit Arya Additional Professor Department of Psychiatry KGMU Lucknow What are addictive substances? Any substance which when taken has an ability to change the person’s consciousness, thinking, mood, behaviour and motor functions Leading to take the substance repeatedly (World Health Organisation, 1992) …Also called as psychoactive substances Layman term: “Drugs” Why are certain substances addictive? Intake of any substance – oral, inhalational, injecting Enters the bloodstream Acts on a specific body part, such as heart, lung, stomach, etc. Addictive substances act on brain Addictive Substances act on brain All substances acting on the brain are not addictive Addictive substances I want to primarily act on a particular take that area/group of neurons in the drug again! brain, Leading the individual to repeatedly administer the addictive / psychoactive substance → “drug seeking” behaviour Addictive substances primarily act on a particular area/group of neurons in the brain. Regions controlling emotions, thinking, Frontal region judgement & memory Mid Brain How are addictive substances different from each other? Broad actions Chemical that the drug class of drugs produces on the brain Source of drug Natural/semi- TYPOLOGY synthetic/synthetic Mode of intake Oral/inhalational/ Availability – parenteral legal/illegal? (injections) Typology – Chemical Class Opioids Alcohol Cannabis Volatile solvents Based on chemical class Stimulants Tobacco Sedative- hypnotics Hallucinogens The usual drug-use
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Diphenhydramine Hydrochloride (CASRN 147-24-0) in F344/N Rats
    NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 355 TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) LJ.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP ‘TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) R. Melnick, Ph.D., Study Scientist NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 September 1989 NTP TR 355 NIH Publication No. 89-2810 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .................. 6 CONTRIBUTORS ............................................................ 7 PEERREVIEWPANEL ........................................................ 8 SUMMARY OF PEER REVIEW COMMENTS ......................................... 9 I. INTRODUCTION ........................................................ 11 I1. MATERIALS AND METHODS .............................................. 21 III. RESULTS ............................................................. 35 RATS ............................................................. 36 MICE ............................................................. 45 GENETIC TOXICOLOGY ............................................... 53 IV.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • HMSA Drug Formulary
    March 23, 2004 MEMORANDUM TO: Participating Pharmacies FROM: John T. Berthiaume, M.D. Medical Director, Pharmacy Management SUBJECT: Updated HMSA Drug Formulary Enclosed is the comprehensive updated formulary, effective April 1. This copy incorporates the changes listed in the Formulary Update sent to you in February. Please replace the current formulary sections in your pharmacy handbook with the enclosed version. If you have any questions, please call an HMSA Provider Teleservice Representative at 948- 6330 on Oahu or 1 (800) 790-4672 from the Neighbor Islands. PM04-010 HMSA DRUG FORMULARY 4/1/04 - Page 1 Code THERAPEUTIC CATEGORY LISTING 1 I. Anti-infectives A. Antibiotics 1. Penicillins - non-penicillinase resistant 2 I. Anti-infectives A. Antibiotics 2. Penicillins - penicillinase resistant 3 I. Anti-infectives A. Antibiotics 3. Cephalosporins 4 I. Anti-infectives A. Antibiotics 4. Fluoroquinolones 5 I. Anti-infectives A. Antibiotics 5. Tetracyclines 6 I. Anti-infectives A. Antibiotics 6. Macrolides 7 I. Anti-infectives A. Antibiotics 7. Vancomycin 8 I. Anti-infectives A. Antibiotics 8. Lincosamides 9 I. Anti-infectives A. Antibiotics 9. Aminoglycoside 10 I. Anti-infectives A. Antibiotics 10. Sulfonamides 11 I. Anti-Infectives A. Antibiotics 11. Vaginal preparations 12 I. Anti-infectives B. Antifungal agents 1. Oral 13 I. Anti-Infectives B. Antifungal agents 2. Vaginal preparations OTC considerations: clotrimazole (Gyne-Lotrimin 3, Mycelex-7), miconazole (Monistat 7), tioconazole (Vagistat-1), butoconazole (Femstat 3) 14 I. Anti-infectives C. Antimalarial 15 I. Anti-infectives D. Antituberculous 16 I. Anti-infectives E. Amebicides 17 I. Anti-infectives F. Antiviral agents 1. Nucleoside Reverse-transcriptase Inhibitors (NRTI) 18 I.
    [Show full text]
  • Brompheniramine Maleate, Pseudoephedrine Hydrochloride
    BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE- brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup Morton Grove Pharmaceuticals, Inc. ---------- Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Oral Syrup 2 mg/30 mg/10 mg per 5 mL Rx only DESCRIPTION Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup is a clear, light pink syrup with a butterscotch flavor. Each 5 mL (1 teaspoonful) contains: Brompheniramine Maleate, USP 2 mg Pseudoephedrine Hydrochloride, USP 30 mg Dextromethorphan Hydrobromide, USP 10 mg Alcohol 0.95% v/v In a palatable, aromatic vehicle. Inactive Ingredients: artificial butterscotch flavor, citric acid anhydrous, dehydrated alcohol, FD&C Red No. 40, glycerin, liquid sugar, methylparaben, propylene glycol, purified water and sodium benzoate. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. The pH range is between 3.0 and 6.0. C16H19BrN2·C4H4O4 M.W. 435.31 Brompheniramine Maleate, USP (±)-2-p-Bromo-α-2-(dimethylamino)ethylbenzylpyridine maleate (1:1) C10H15NO · HCl M.W. 201.69 Pseudoephedrine Hydrochloride, USP (+)-Pseudoephedrine hydrochloride C18H25NO · HBr · H2O M.W. 370.32 Dextromethorphan Hydrobromide, USP 3-Methoxy-17-methyl-9α, 13α, 14α -morphinan hydrobromide monohydrate Antihistamine/Nasal Decongestant/Antitussive syrup for oral administration. CLINICAL PHARMACOLOGY Brompheniramine maleate is a
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Product Information
    PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE® (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine with anticholinergic properties Dexchlorpheniramine maleate (CAS no. 2438-32-6) is described chemically as (+)-2-[p- chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine maleate (1:1). It has the empirical formula of C16H19ClN2.C4H4O4 and the following structural formula: Dexchlorpheniramine maleate is a white, odourless, crystalline powder which in aqueous solution has a pH of between 4 and 5. It is freely soluble in water, soluble in alcohol and in chloroform, but only slightly soluble in benzene or ether. PHARMACOLOGY Pharmacodynamics Mechanism of Action: Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. H1-antagonists are structurally similar to anticholinergic agents and therefore possess the potential to exhibit anticholinergic properties of varying
    [Show full text]
  • Report Update 1
    Drug Class Review on Newer Antihistamines Final Report Update 1 April 2006 Original Report Date: November 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior version of this report can be accessed at the DERP website. Final Report Update #1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION.............................................................................................................................................................4 SCOPE AND KEY QUESTIONS.............................................................................................................................6
    [Show full text]